NO20030233L - Process for finding compounds suitable for the treatment and / or prophylaxis of obesity - Google Patents

Process for finding compounds suitable for the treatment and / or prophylaxis of obesity

Info

Publication number
NO20030233L
NO20030233L NO20030233A NO20030233A NO20030233L NO 20030233 L NO20030233 L NO 20030233L NO 20030233 A NO20030233 A NO 20030233A NO 20030233 A NO20030233 A NO 20030233A NO 20030233 L NO20030233 L NO 20030233L
Authority
NO
Norway
Prior art keywords
prophylaxis
obesity
treatment
compounds suitable
finding compounds
Prior art date
Application number
NO20030233A
Other languages
Norwegian (no)
Other versions
NO20030233D0 (en
Inventor
Johannes Hebebrand
Jochen Antel
Ulf Preuschoff
Samuel David
Holger Sann
Michael Weske
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of NO20030233D0 publication Critical patent/NO20030233D0/en
Publication of NO20030233L publication Critical patent/NO20030233L/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20030233A 2000-07-20 2003-01-17 Process for finding compounds suitable for the treatment and / or prophylaxis of obesity NO20030233L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10035227A DE10035227A1 (en) 2000-07-20 2000-07-20 Selection and use of lipogenesis inhibitors for the treatment and prevention of obesity
PCT/EP2001/008051 WO2002007821A1 (en) 2000-07-20 2001-07-12 Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity

Publications (2)

Publication Number Publication Date
NO20030233D0 NO20030233D0 (en) 2003-01-17
NO20030233L true NO20030233L (en) 2003-03-19

Family

ID=7649538

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030233A NO20030233L (en) 2000-07-20 2003-01-17 Process for finding compounds suitable for the treatment and / or prophylaxis of obesity

Country Status (27)

Country Link
EP (1) EP1307262B1 (en)
JP (1) JP2004504053A (en)
KR (1) KR100818827B1 (en)
CN (1) CN1443085B (en)
AR (1) AR028730A1 (en)
AT (1) ATE278441T1 (en)
AU (2) AU2001277534B9 (en)
BR (1) BR0112547A (en)
CA (1) CA2416647A1 (en)
CZ (1) CZ2003156A3 (en)
DE (2) DE10035227A1 (en)
DZ (1) DZ3393A1 (en)
ES (1) ES2230346T3 (en)
HK (1) HK1057499A1 (en)
HU (1) HUP0302309A3 (en)
IL (2) IL153971A0 (en)
MX (1) MXPA02012907A (en)
NO (1) NO20030233L (en)
NZ (1) NZ523960A (en)
PL (1) PL201165B1 (en)
PT (1) PT1307262E (en)
RU (1) RU2268721C2 (en)
SK (1) SK287607B6 (en)
TR (1) TR200402670T4 (en)
TW (1) TWI274157B (en)
UA (1) UA74588C2 (en)
WO (1) WO2002007821A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997370B (en) 2004-05-19 2011-06-01 索尔瓦药物有限公司 Use of n-sulfamoyl-n'-arylpiperazines in preparing medicine for the prophylaxis or treatment of obesity and related conditions
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
KR20080012360A (en) 2005-05-20 2008-02-11 얀센 파마슈티카 엔.브이. Process for preparation of sulfamide derivatives
AR057570A1 (en) 2005-11-14 2007-12-05 Solvay Pharm Gmbh DERIVATIVES OF N-SULFAMOIL-N'-BENZOPIRANOPIPERIDINAS ESPIROCONDENSADAS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, A PROCEDURE FOR THEIR PREPARATION AND ITS USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY ISOIDAS IIB
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
TW200812573A (en) 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
NO2106260T3 (en) 2007-01-25 2018-05-05
US8809385B2 (en) 2008-06-23 2014-08-19 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
KR20150023405A (en) * 2012-05-24 2015-03-05 베바 파마슈티칼스 엘티디 A Method of Improving Liver Function
CN106770611B (en) * 2016-12-22 2019-01-29 广西师范大学 A method of entering mitochondria for cell in-situ detection small molecule compound
RU2771430C1 (en) * 2021-09-21 2022-05-04 Федеральное государственное бюджетное научное учреждение "Научный центр неврологии" (ФГБНУ НЦН) Method for the quantitative determination of anticonvulsants in the blood plasma of patients with epilepsy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552897A (en) * 1983-02-01 1985-11-12 American Cyanamid Company Salts of 1-(aminodihalophenyl)-2-aminoethanols and antilipogenic compositions prepared therefrom
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
JPH08502969A (en) * 1992-10-29 1996-04-02 ジェネンテク,インコーポレイテッド How to prevent or treat obesity
AU693478B2 (en) * 1994-11-10 1998-07-02 Metabolic Pharmaceuticals Limited Treatment of obesity
CA2258893C (en) * 1996-06-28 2005-06-14 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant sulfamate derivatives useful in treating obesity
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor

Also Published As

Publication number Publication date
HK1057499A1 (en) 2004-04-08
ATE278441T1 (en) 2004-10-15
RU2268721C2 (en) 2006-01-27
PT1307262E (en) 2004-12-31
EP1307262B1 (en) 2004-10-06
CN1443085A (en) 2003-09-17
IL153971A (en) 2009-07-20
AU2001277534B9 (en) 2006-02-23
UA74588C2 (en) 2006-01-16
EP1307262A1 (en) 2003-05-07
AU7753401A (en) 2002-02-05
TWI274157B (en) 2007-02-21
CA2416647A1 (en) 2003-01-20
BR0112547A (en) 2003-07-01
SK287607B6 (en) 2011-03-04
IL153971A0 (en) 2003-07-31
KR100818827B1 (en) 2008-04-01
MXPA02012907A (en) 2003-09-22
AR028730A1 (en) 2003-05-21
HUP0302309A3 (en) 2005-06-28
PL201165B1 (en) 2009-03-31
NO20030233D0 (en) 2003-01-17
NZ523960A (en) 2004-12-24
DE50104023D1 (en) 2004-11-11
DZ3393A1 (en) 2002-01-31
SK612003A3 (en) 2003-06-03
AU2001277534B2 (en) 2005-09-29
WO2002007821A1 (en) 2002-01-31
CN1443085B (en) 2010-04-28
DE10035227A1 (en) 2002-01-31
PL363518A1 (en) 2004-11-29
KR20030022284A (en) 2003-03-15
JP2004504053A (en) 2004-02-12
HUP0302309A2 (en) 2003-11-28
TR200402670T4 (en) 2004-11-22
ES2230346T3 (en) 2005-05-01
CZ2003156A3 (en) 2003-06-18

Similar Documents

Publication Publication Date Title
NO20030233L (en) Process for finding compounds suitable for the treatment and / or prophylaxis of obesity
NO20054369D0 (en) Use of an IBAT inhibitor for the treatment and prophylaxis of constipation
NO20013380L (en) 2-aminobenzoxazinone derivatives for the treatment of obesity
NO20041216L (en) Imidazole-4-carboxamide derivatives, preparation and use thereof for the treatment of obesity
NO20020770L (en) Use of monoamine oxidase inhibitors for the manufacture of drugs suitable for the treatment of obesity
AU8870701A (en) Materials and methods for the treatment or prevention of obesity
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
NO20052476D0 (en) 2-alkyl (2-amino-3-aryl-propionyl) -piperazine derivatives and related compounds as melanocortin receptor ligands for the treatment of obesity.
NO20013381D0 (en) 2-oxybenzoxazinone derivatives for the treatment of obesity
AU2001271567A1 (en) Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
NO20035610L (en) Process for the treatment of liquid hydrocarbon
NO20044195L (en) Biophosphonic acids for the treatment and prevention of osteoporosis
NO20052009D0 (en) Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
SI1231920T1 (en) Use of epinastin for the treatment of allergic rhinitis/conjunctivitis
GB2418025B (en) Device for the prevention or treatment of ulcers
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
DK1455794T3 (en) CIC-2 channel opener for the treatment of gastric or intestinal ulcer
AU2003263760A1 (en) Methods for the treatment or prevention of obesity
NO20033498D0 (en) Process for the treatment and drying of wood
AU2001277534A1 (en) Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity
AU2002364171A8 (en) Materials and methods for the treatment or prevention of obesity
NO20034123L (en) Procedure for the treatment of fuel
NO20026219L (en) Compounds for the treatment of impaired fundic relaxation
PT1412343E (en) Compounds, which are potent inhibitors of na+/ca2+ exchange mechanism and are useful in the treatment of arrhythmias
SI1562577T1 (en) Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by thalidomide